RE:RE:Roche & Tecentriq.As I previously stated the upcoming release of GOBLET Phase 2 clinical trial using data with Roche's CPI Tecentriq is the set up for the potential of granting of an FDA Accelerated Approval with PanCan Precision Promise Phase 3 trial using Roche's Tecentriq as the confirmatory trial, pursuant to the FDA's post approval requirements.
The upcoming PanCan Precision Promise Phase 3 trial with pelareorep + Tecentriq also will be the second clinical trial with this combination and would further satisfy the FDA's requirement that 2 separate trials with the same combination be conducted to fulfill the FDA's drug conditional accelerated approval, ultimately followed by a full approval with further evidence of Phase 3 effectiveness.